moxifloxacin

Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibiotic (8-methoxy-fluoroquinolone) developed by Bayer. It exerts its bactericidal effect primarily by inhibiting bacterial DNA gyrase (gyrA subunit) and topoisomerase IV (parC or parE subunits), enzymes essential for DNA replication and transcription. This inhibition leads to disruption of DNA synthesis and ultimately bacterial cell death. Moxifloxacin demonstrates broad-spectrum activity against Gram-positive bacteria, Gram-negative bacteria, anaerobes, atypical pathogens such as Mycoplasma and Chlamydia species, as well as Mycobacterium tuberculosis. It is used clinically to treat respiratory tract infections (including community-acquired pneumonia), acute bacterial sinusitis, acute exacerbations of chronic bronchitis, intra-abdominal infections, skin and soft tissue infections, conjunctivitis (as ophthalmic solution), anthrax exposure prophylaxis/treatment, endocarditis adjunctive therapy in some cases, meningitis adjunctive therapy in some cases and tuberculosis[1][4][5]. The drug is available orally or intravenously as moxifloxacin hydrochloride; ophthalmic formulations are also available.

Brand names

AveloxAvaloxAvelonVigamoxMoxeza

Other names

莫西沙星moxifloxacin hydrochloride